AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 291: E1372-E1380, 2006. First published July 25, 2006; doi:10.1152/ajpendo.00480.2005
0193-1849/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
291/6/E1372    most recent
00480.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, C.-S. J.
Right arrow Articles by Mountjoy, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, C.-S. J.
Right arrow Articles by Mountjoy, K. G.

Peripherally administered desacetyl {alpha}-MSH and {alpha}-MSH both influence postnatal rat growth and associated rat hypothalamic protein expression

Chia-Shan Jenny Wu,1 David R. Greenwood,2 Janine M. Cooney,3 Dwayne J. Jensen,3 Michele A. Tatnell,1 Garth J. S. Cooper,4 and Kathleen G. Mountjoy1,5

1Department of Physiology, 5Department of Molecular Medicine and Pathology, 4School of Biological Sciences, University of Auckland; 2HortResearch, Mt. Albert, Auckland; and 3HortResearch, Ruakura, Hamilton, New Zealand

Submitted 3 October 2005 ; accepted in final form 15 July 2006

Desacetyl {alpha}-MSH predominates over {alpha}-MSH during development, but whether it is biologically active and has a physiological role is unclear. We compared the effects of 0.3 µg·g–1·day–1 desacetyl {alpha}-MSH with that of 0.3 µg·g–1·day–1 {alpha}-MSH on postnatal body growth by administering the peptides subcutaneously daily for postnatal days 0–14 and also used a two-dimensional gel electrophoresis gel-based proteomic approach to analyze protein changes in hypothalami, the relay center for body weight and growth regulation, after 14 days of treatment. We found that the growth rate between days 1 and 10 was significantly decreased by desacetyl {alpha}-MSH but not by {alpha}-MSH, but by day 14, a time reported for development of a mature pattern of hypothalamic innervation, both peptides had significantly increased neonatal growth compared with PBS-treated control rats. Desacetyl {alpha}-MSH significantly increased spleen weight, but {alpha}-MSH had no effect. {alpha}-MSH significantly decreased kidney weight, but desacetyl {alpha}-MSH had no effect. Both desacetyl {alpha}-MSH and {alpha}-MSH significantly decreased brain weight. By 14 days, both peptides significantly changed expression of a number of hypothalamic proteins, specifically metabolic enzymes, cytoskeleton, signaling, and stress response proteins. We show that peripherally administered desacetyl {alpha}-MSH is biologically active and induces responses that can differ from those for {alpha}-MSH. In conclusion, desacetyl {alpha}-MSH appears to be an important regulator of neonatal rat growth.

melanocortin peptides; {alpha}-melanocyte-stimulating hormone; melanocortin receptors; proopiomelanocortin; hypothalamus


Address for reprint requests and other correspondence: K. G. Mountjoy Dept. of Physiology, School of Medical Sciences, University of Auckland, Auckland 1023, New Zealand (e-mail: kmountjoy{at}auckland.ac.nz)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.